Orna Therapeutics

620 Memorial Drive, 2nd Floor
Cambridge
MA
02139
United States

NextGen Class of 2022
Show jobs for this employer

6 articles with Orna Therapeutics

  • BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
  • From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between. 
  • As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers.
  • Robert Mabry, Ph.D. joins as Chief Scientific Officer from Takeda Pharmaceuticals and Nishla Keiser, Ph.D., J.D. appointed as Chief Legal and Strategy Officer from Intellia Therapeutics.

  • With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
  • Orna, which began as an academic query at the Massachusetts Institute of Technology (MIT), is a biotechnology company creating fully engineered circular RNA, or O-shaped RNA therapies for the treatment of cancer, autoimmune, and genetic disorders.